US04280A1007
© BusinessWire
15.12.2025
ARWR
LISTED
NASDAQ
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
News Preview
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on December 12, 2025, the Company’s Board of Directors approved “inducement” grants to 78 new employees under Rule 5635(c)(4) of the NASDAQ Listing Rules. The grants entitle employees, in aggregate, to receive up to 14...
Themefolio
Profiler
Peergroup
© BusinessWire
08.12.2025
ARWR
LISTED
NASDAQ
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies
News Preview
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-MAPT, the company’s investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for tauopathies including Alzheimer’s disease, a progressive neurodegenerative disease characteriz...
Themefolio
Profiler
Peergroup
© BusinessWire
02.12.2025
ARWR
LISTED
NASDAQ
Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia
News Preview
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the United States Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to investigational plozasiran as an adjunct to diet to reduce triglyceride (TG) levels in adults with severe hypertriglyceridemia (SHTG) (TG levels greater than or equal to 500 mg/dL)...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© BusinessWire
01.12.2025
ARWR
LISTED
NASDAQ
Arrowhead Pharmaceuticals to Participate in Upcoming December 2025 Conferences
News Preview
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:
Piper Sandler 37th Annual Healthcare Conference – December 2-4, 2025
Type: Fireside Chat Presentation
Date/Time: December 3, 2025, 10:30 a.m. EST
8th Annual Evercore Healthcare Conference – December 2-4, 2025
Typ...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
25.11.2025
ARWR
LISTED
NASDAQ
Arrowhead Pharmaceuticals Reports 2025 Fiscal Year-End Results
News Preview
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its 2025 fiscal year ended September 30, 2025. The Company is hosting a conference call today, November 25, 2025, at 4:30 p.m. ET to discuss the results.
“The recent FDA approval of REDEMPLO, indicated as an adjunct to diet to reduce triglycerides in adults with...
Themefolio
Profiler
Peergroup
© BusinessWire
24.11.2025
ARWR
LISTED
NASDAQ
Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics
News Preview
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has earned a $200 million milestone payment from Sarepta Therapeutics (NASDAQ: SRPT). The milestone was earned when Arrowhead achieved the second development milestone event in a Phase 1/2 clinical study of ARO-DM1, also called SRP-1003, an investigational RNA interference (RNA...
Themefolio
Profiler
Peergroup
© BusinessWire
18.11.2025
ARWR
LISTED
NASDAQ
Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
News Preview
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the U.S. Food and Drug Administration (FDA) has approved REDEMPLO (plozasiran), a small interfering RNA (siRNA) medicine, as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS). FCS is a severe, rare disease, with an estimated 6,500 pe...
Themefolio
Profiler
Peergroup
© BusinessWire
06.11.2025
ARWR
LISTED
NASDAQ
Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Year-End Results
News Preview
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on November 25, 2025, at 4:30 p.m. ET to discuss its financial results for the 2025 fiscal year ended September 30, 2025.
Webcast and Conference Call Details
Investors may access a live audio webcast on the Events and Presentations page...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ARWR
LISTED
NASDAQ
Arrowhead Pharmaceuticals to Participate in Upcoming November 2025 Conferences
News Preview
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:
American Heart Association (AHA) Scientific Sessions 2025 – November 7-10, 2025
Title: Rationale and Design: Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Zodasiran in Adoles...
Themefolio
Profiler
Peergroup
© BusinessWire
28.10.2025
ARWR
LISTED
NASDAQ
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
News Preview
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on October 24, 2025, the Company’s Board of Directors approved “inducement” grants to 84 new employees under Rule 5635(c)(4) of the NASDAQ Listing Rules. The grants entitle employees, in aggregate, to receive up to 127...
Themefolio
Profiler
Peergroup
© BusinessWire
21.10.2025
ARWR
LISTED
NASDAQ
Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Novartis
News Preview
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that a global licensing and collaboration agreement with Novartis, previously announced on September 2, 2025, has now closed. Closing of the transaction was subject to the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and...
Themefolio
Profiler
Peergroup
© BusinessWire
07.10.2025
ARWR
LISTED
NASDAQ
Arrowhead Pharmaceuticals Files CTA for Investigational ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
News Preview
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has filed a request for regulatory clearance to initiate a Phase 1/2a clinical trial of ARO-DIMER-PA, the company’s investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for atherosclerotic cardiovascular disease (ASCVD) due to mixed hyper...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
11.09.2025
ARWR
LISTED
NASDAQ
Arrowhead Pharmaceuticals Files Complaint for Declaratory Judgment Against Ionis Pharmaceuticals
News Preview
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that yesterday it filed a Complaint for Declaratory Judgment in the United States District Court for the District of Delaware against Ionis Pharmaceuticals, Inc., to declare that Ionis’s United States Patent No. 9,593,333 (“the ’333 patent”) is invalid and not infringed by Arrowhead’s...
Themefolio
Profiler
Peergroup
© BusinessWire
10.09.2025
ARWR
LISTED
NASDAQ
Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies
News Preview
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has filed a request for regulatory clearance to initiate a Phase 1/2a clinical trial of ARO-MAPT, the company’s investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for tauopathies including Alzheimer’s disease, a progressive neurodegener...
Themefolio
Profiler
Peergroup
© BusinessWire
02.09.2025
ARWR
LISTED
NASDAQ
Arrowhead Pharmaceuticals and Novartis Enter into a Global License and Collaboration Agreement
News Preview
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced a global licensing and collaboration agreement with Novartis for ARO-SNCA, Arrowhead’s preclinical stage siRNA therapy against alpha-synuclein for the treatment of synucleinopathies, such as Parkinson’s Disease, and for other additional collaboration targets that will utilize Arrowhead...
Themefolio
Profiler
Peergroup
© BusinessWire
27.08.2025
ARWR
LISTED
NASDAQ
Arrowhead Pharmaceuticals to Participate in Upcoming September 2025 Conferences
News Preview
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:
European Society of Cardiology (ESC) Congress 2025 – August 29 - September 1, 2025
Title: A Randomized, Placebo-controlled Phase 3 Study of Plozasiran in Patients With FCS: Interim Analysis of Open Label Extensio...
Themefolio
Profiler
Peergroup
© BusinessWire
13.08.2025
ARWR
LISTED
NASDAQ
Arrowhead Pharmaceuticals Redeems Approximately $50 Million of Arrowhead Stock and Will Receive Approximately $50 Million in Cash in Satisfaction of Milestone from Sarepta Therapeutics
News Preview
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has elected to receive approximately $50 million worth of Arrowhead common stock and approximately $50 million in cash from Sarepta Therapeutics, satisfying the payment of a $100 million milestone owed to Arrowhead. This agreement pertains only to the $100 million milestone, wh...
Themefolio
Profiler
Peergroup
© BusinessWire
01.08.2025
ARWR
LISTED
NASDAQ
Arrowhead Subsidiary Visirna Sells Rights to Hypertriglyceridemia Candidate Plozasiran in Greater China to Sanofi
News Preview
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced the signing of an asset purchase agreement between Sanofi and Visirna Therapeutics, a majority-owned subsidiary of Arrowhead created to develop and commercialize four of Arrowhead’s investigational cardiometabolic candidates in Greater China. Under the terms, Sanofi will acquire rights...
Themefolio
Profiler
Peergroup
© BusinessWire
28.07.2025
ARWR
LISTED
NASDAQ
Arrowhead Pharmaceuticals Earns $100 Million Milestone from Sarepta Therapeutics
News Preview
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has earned a $100 million milestone payment from Sarepta Therapeutics (NASDAQ: SRPT). The milestone was triggered when Arrowhead reached the first of two prespecified enrollment targets and subsequent authorization to dose escalate in a Phase 1/2 clinical study of ARO-DM1, an i...
Themefolio
Profiler
Peergroup
© BusinessWire
24.07.2025
ARWR
LISTED
NASDAQ
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
News Preview
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on July 22, 2025, the Company’s Board of Directors approved “inducement” grants to 38 new employees under Rule 5635(c)(4) of the NASDAQ Listing Rules. The grants entitle employees, in aggregate, to receive up to 52,680...
Themefolio
Profiler
Peergroup
© BusinessWire
23.07.2025
ARWR
LISTED
NASDAQ
Arrowhead Pharmaceuticals Issues Statement on the Status of its Ongoing Agreement with Sarepta Therapeutics
News Preview
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today issued a statement to address questions about the status of its ongoing Exclusive License and Collaboration Agreement with Sarepta Therapeutics. Arrowhead continues to conduct clinical and non-clinical studies as stipulated in the agreement, and it expects Sarepta to continue to meet its require...
Themefolio
Profiler
Peergroup
© BusinessWire
21.07.2025
ARWR
LISTED
NASDAQ
Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Third Quarter Results
News Preview
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on August 7, 2025, at 4:30 p.m. ET to discuss its financial results for the fiscal 2025 third quarter ended June 30, 2025.
Webcast and Conference Call and Details
Investors may access a live audio webcast on the Events and Presentatio...
Themefolio
Profiler
Peergroup
© BusinessWire
08.07.2025
ARWR
LISTED
NASDAQ
Arrowhead Pharmaceuticals Initiates Phase 3 YOSEMITE Study of Investigational Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia
News Preview
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has dosed the first subject in the YOSEMITE Phase 3 clinical trial of zodasiran, the company’s investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for homozygous familial hypercholesterolemia (HoFH), a rare genetic condition that leads t...
Themefolio
Profiler
Peergroup
© BusinessWire
23.06.2025
ARWR
LISTED
NASDAQ
Arrowhead Pharmaceuticals Completes Enrollment in SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 Studies of Plozasiran
News Preview
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has completed enrollment in SHASTA-3, SHASTA-4, and MUIR-3, the company’s global Phase 3 clinical studies designed to support regulatory submissions for marketing approval of investigational plozasiran in the treatment of severe hypertriglyceridemia. Arrowhead anticipates compl...
Themefolio
Profiler
Peergroup
© BusinessWire
02.06.2025
ARWR
LISTED
NASDAQ
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity
News Preview
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-ALK7, the company’s investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for obesity. ARO-ALK7 is designed to intervene in a known pathway that signals the body to store f...
Themefolio
Profiler
Peergroup
© BusinessWire
29.05.2025
ARWR
LISTED
NASDAQ
Arrowhead Pharmaceuticals to Participate in June 2025 Investor Conferences
News Preview
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming investor events:
Jefferies Global Healthcare Conference – June 4-5, 2025
Type: Fireside Chat Presentation
Date/Time: June 4, 2025, 9:20 a.m. EDT
46th Annual Goldman Sachs Global Healthcare Conference – June 9-11, 2025...
Themefolio
Profiler
Peergroup
© BusinessWire
12.05.2025
ARWR
LISTED
NASDAQ
Arrowhead Pharmaceuticals Reports Fiscal 2025 Second Quarter Results
News Preview
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2025 second quarter ended March 31, 2025. The Company is hosting a conference call today, May 12, 2025, at 4:30 p.m. ET to discuss the results.
“Arrowhead is in a strong and stable position as a business, and we have made meaningful progress towards ou...
Themefolio
Profiler
Peergroup
© BusinessWire
07.05.2025
ARWR
LISTED
NASDAQ
Arrowhead Pharmaceuticals to Participate in May 2025 Investor Conferences
News Preview
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming investor events:
BofA Securities 2025 Health Care Conference – May 13-15, 2025
Type: Fireside Chat Presentation
Date/Time: May 14, 2025, 11:20 a.m. PDT
2025 RBC Capital Markets Global Healthcare – May 20-21, 2025
Type: F...
Themefolio
Profiler
Peergroup
© BusinessWire
30.04.2025
ARWR
LISTED
NASDAQ
Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Second Quarter Results
News Preview
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on May 12, 2025, at 4:30 p.m. ET to discuss its financial results for the fiscal 2025 second quarter ended March 31, 2025.
Webcast and Conference Call and Details
Investors may access a live audio webcast on the Events and Presentations...
Themefolio
Profiler
Peergroup
© BusinessWire
15.04.2025
ARWR
LISTED
NASDAQ
Arrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial Officer
News Preview
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that, effective May 13, 2025, Arrowhead’s Chief Financial Officer, Ken Myszkowski, will retire after 16 years of service to the company and will be succeeded by Daniel Apel, who has been appointed as the company’s new Chief Financial Officer. Mr. Myszkowski will continue to serve as an...
Themefolio
Profiler
Peergroup
© BusinessWire
04.04.2025
ARWR
LISTED
NASDAQ
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
News Preview
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on April 3, 2025, the Company’s Board of Directors approved “inducement” grants to 21 new employees under Rule 5635(c)(4) of the NASDAQ Listing Rules. The grants entitle employees, in aggregate, to receive up to 34,190...
Themefolio
Profiler
Peergroup
© BusinessWire
10.03.2025
ARWR
LISTED
NASDAQ
Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy
News Preview
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced topline results from Part 2 of a Phase 1/2 clinical study of ARO-C3, the company’s investigational RNA interference (RNAi) therapeutic designed to reduce liver production of complement component 3 (C3) as a potential therapy for various complement mediated diseases. The company plans t...
Themefolio
Profiler
Peergroup
© BusinessWire
06.03.2025
ARWR
LISTED
NASDAQ
Arrowhead Pharmaceuticals Showcases Two Clinical-Stage RNAi-Based Candidates to Treat Obesity and Metabolic Diseases
News Preview
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced presentation of preclinical data supporting the advancement of two first-in-class clinical stage, RNAi-based investigational therapeutics being developed for the treatment of obesity and metabolic diseases. The two candidates, ARO-INHBE and ARO-ALK7, have the potential to reduce body w...
Themefolio
Profiler
Peergroup
© BusinessWire
28.02.2025
ARWR
LISTED
NASDAQ
Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (FCS)
News Preview
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) marks Rare Disease Day with the expansion of the We’ll Get There Soon campaign, initially launched for healthcare providers in November 2024. This new phase introduces a dedicated educational website, www.LowerMyTGs.com, and the Spotlight on FCS white paper, which provides essential resources and supp...
Themefolio
Profiler
Peergroup
© BusinessWire
25.02.2025
ARWR
LISTED
NASDAQ
Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ALK7 for Treatment of Obesity
News Preview
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced preclinical results on ARO-ALK7, the company’s investigational RNA interference (RNAi) therapeutic targeting Activin receptor-like kinase 7 (ALK7) being developed as a potential treatment for obesity. The results were presented in a poster at the Keystone Symposia on Obesity and Adipos...
Themefolio
Profiler
Peergroup
© BusinessWire
10.02.2025
ARWR
LISTED
NASDAQ
Arrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter Results
News Preview
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2025 first quarter ended December 31, 2024. The Company is hosting a conference call today, February 10, 2025, at 4:30 p.m. ET to discuss the results.
“During the recent period, Arrowhead signed and closed a potentially transformational licensing and...
Themefolio
Profiler
Peergroup
© BusinessWire
10.02.2025
ARWR
LISTED
NASDAQ
Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics
News Preview
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the global licensing and collaboration agreement with Sarepta Therapeutics (NASDAQ: SRPT) announced on November 26, 2024, has now closed. Closing of the transaction was subject to the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvement...
Themefolio
Profiler
Peergroup
© BusinessWire
22.01.2025
ARWR
LISTED
NASDAQ
Arrowhead Pharmaceuticals to Webcast Fiscal 2025 First Quarter Results
News Preview
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 10, 2025, at 4:30 p.m. ET to discuss its financial results for the fiscal 2025 first quarter ended December 31, 2024.
Webcast and Conference Call and Details
Investors may access a live audio webcast on the Events and Pres...
Themefolio
Profiler
Peergroup
© BusinessWire
17.01.2025
ARWR
LISTED
NASDAQ
Arrowhead Pharmaceuticals Announces Acceptance of New Drug Application by U.S. FDA of Plozasiran for the Treatment of Familial Chylomicronemia Syndrome
News Preview
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for investigational plozasiran for the treatment of familial chylomicronemia syndrome (FCS), a severe and rare genetic disease. The FDA provided a Prescription Drug User Fee Act (PDUFA) action...
Themefolio
Profiler
Peergroup
© BusinessWire
23.12.2024
ARWR
LISTED
NASDAQ
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity
News Preview
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-INHBE, the company’s investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for obesity. Arrowhead also filed recently a request for regulatory clearance to initiate a clini...
Themefolio
Profiler
Peergroup
© BusinessWire
19.12.2024
ARWR
LISTED
NASDAQ
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
News Preview
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on December 13, 2024, the Company’s Board of Directors approved “inducement” grants to 20 new employees under Rule 5635(c)(4) of the NASDAQ Listing Rules. The grants entitle employees, in aggregate, to receive up to 44...
Themefolio
Profiler
Peergroup
© BusinessWire
11.12.2024
ARWR
LISTED
NASDAQ
Arrowhead Pharmaceuticals Presents Interim Clinical Data on ARO-CFB for the Treatment of Complement Mediated Diseases
News Preview
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim results from a Phase 1/2a clinical study of ARO-CFB, the company’s investigational RNA interference (RNAi) therapeutic targeting complement factor B being developed as a potential treatment for complement mediated diseases. The data were presented today, December 11, 2024, at t...
Themefolio
Profiler
Peergroup
© BusinessWire
03.12.2024
ARWR
LISTED
NASDAQ
Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity
News Preview
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has filed a request for regulatory clearance to initiate a Phase 1/2a clinical trial of ARO-ALK7, the company’s second investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for obesity. ARO-ALK7 is the first RNAi-based therapy to directly...
Themefolio
Profiler
Peergroup
© BusinessWire
02.12.2024
ARWR
LISTED
NASDAQ
Arrowhead Pharmaceuticals to Participate in Upcoming December 2024 Conferences
News Preview
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:
Piper Sandler 36th Annual Healthcare Conference – December 3-5, 2024
Type: Fireside Chat Presentation
Date/Time: December 3, 2024, 1:30 p.m. EST
7th Annual Evercore ISI HealthCONx Conference – December 3-5, 202...
Themefolio
Profiler
Peergroup
© BusinessWire
26.11.2024
ARWR
LISTED
NASDAQ
Arrowhead Pharmaceuticals Reports 2024 Fiscal Year-End Results
News Preview
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its 2024 fiscal year ended September 30, 2024. The Company is hosting a conference call today, November 26, 2024, at 4:30 p.m. ET to discuss the results.
“Arrowhead is well positioned, both individually and with partners, to advance and ultimately commercialize...
Themefolio
Profiler
Peergroup
© BusinessWire
26.11.2024
ARWR
LISTED
NASDAQ
Arrowhead Pharmaceuticals Announces Global License and Collaboration Agreement with Sarepta Therapeutics for Multiple Clinical and Preclinical Programs
News Preview
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced a global licensing and collaboration agreement with Sarepta Therapeutics (NASDAQ: SRPT). Upon closing, Arrowhead will receive $825 million, consisting of $500 million cash and $325 million as an equity investment priced at a 35% premium. Arrowhead also receives $250 million to be paid...
Themefolio
Profiler
Peergroup
© BusinessWire
18.11.2024
ARWR
LISTED
NASDAQ
Arrowhead Pharmaceuticals Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome
News Preview
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for investigational plozasiran for the treatment of familial chylomicronemia syndrome (FCS), a severe and rare genetic disease which currently has no FDA approved treatments. Arrowhead also in...
Themefolio
Profiler
Peergroup
© BusinessWire
18.11.2024
ARWR
LISTED
NASDAQ
Arrowhead Pharmaceuticals Presents New Data at AHA24 from PALISADE Phase 3 Study and Open-Label Extension from MUIR and SHASTA-2 Studies of Plozasiran
News Preview
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced new results from the Phase 3 PALISADE study and the open-label extension from the Phase 2 MUIR and SHASTA-2 studies of investigational plozasiran. These data were presented in two oral presentations at the American Heart Association Scientific Sessions 2024 (AHA24) and PALISADE data wa...
Themefolio
Profiler
Peergroup
© BusinessWire
05.11.2024
ARWR
LISTED
NASDAQ
Arrowhead Pharmaceuticals to Webcast 2024 Fiscal Year End Results
News Preview
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it will host a webcast and conference call on November 26, 2024, at 4:30 p.m. ET to discuss its financial results for the 2024 fiscal year ended September 30, 2024.
Webcast and Conference Call and Details
Investors may access a live audio webcast on the Events and Presentations p...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2024
ARWR
LISTED
NASDAQ
Arrowhead Pharmaceuticals to Participate in Upcoming November 2024 Conferences
News Preview
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:
15th Annual American Conference on Pharmacometrics (ACoP 2024) – November 10-13, 2024
Title: Population K-PD Modeling of Plozasiran (ARO-APOC3), a GalNAc-siRNA Conjugate, for the Treatment of Patients with Severe H...
Themefolio
Profiler
Peergroup
© BusinessWire
01.11.2024
ARWR
LISTED
NASDAQ
Arrowhead Pharmaceuticals Launches New Disease Awareness Campaign, ‘We’ll Get There Soon,’ to Inspire Hope for the Rare Disease Community Affected by Familial Chylomicronemia Syndrome
News Preview
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today, on FCS Awareness Day, announced the launch of a new disease awareness campaign, 'We'll Get There Soon,' to bring hope to the rare disease community affected by Familial Chylomicronemia Syndrome (FCS). The campaign seeks to raise awareness about FCS, a severe and rare condition marked by persist...
Themefolio
Profiler
Peergroup
© BusinessWire
14.10.2024
ARWR
LISTED
NASDAQ
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
News Preview
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on October 11, 2024, the Company’s Board of Directors approved “inducement” grants to 34 new employees under Rule 5635(c)(4) of the NASDAQ Listing Rules. The grants entitle employees, in aggregate, to receive up to 66,...
Themefolio
Profiler
Peergroup
© BusinessWire
23.09.2024
ARWR
LISTED
NASDAQ
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity
News Preview
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has filed for regulatory clearance to initiate a Phase 1/2a clinical trial of ARO-INHBE, the company’s investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for obesity. Arrowhead also plans to file for regulatory clearance before the end...
Themefolio
Profiler
Peergroup
© BusinessWire
10.09.2024
ARWR
LISTED
NASDAQ
Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran
News Preview
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the United States Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to investigational plozasiran as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS), a severe and rare genetic disease characterized by...
Themefolio
Profiler
Peergroup
© BusinessWire
02.09.2024
ARWR
LISTED
NASDAQ
Arrowhead Pharmaceuticals Presents New Pivotal Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome
News Preview
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced results from the Phase 3 PALISADE study of investigational plozasiran in patients with familial chylomicronemia syndrome (FCS), a severe and rare genetic disease which currently has no approved treatments in the U.S. PALISADE successfully met its primary endpoint and all multiplicity-c...
Themefolio
Profiler
Peergroup
© BusinessWire
21.08.2024
ARWR
LISTED
NASDAQ
Arrowhead Pharmaceuticals to Present New Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome
News Preview
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will present new Phase 3 clinical data from the PALISADE study of plozasiran (ARO-APOC3) at the European Society of Cardiology (ESC) Congress 2024, being held in London August 30 through September 2, 2024. The company will also host a virtual analyst and investor event on Septe...
Themefolio
Profiler
Peergroup
© BusinessWire
14.08.2024
ARWR
LISTED
NASDAQ
Arrowhead Pharmaceuticals to Advance Two New RNAi-Based Obesity Candidates, ARO-INHBE and ARO-ALK7, Into Clinical Studies
News Preview
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented preclinical data and detailed its plans to advance two next generation RNAi-based candidates, ARO-INHBE and ARO-ALK7, into upcoming clinical studies for the treatment of obesity and metabolic diseases. In preclinical studies to date, these candidates demonstrated the potential to reduc...
Themefolio
Profiler
Peergroup
© BusinessWire
08.08.2024
ARWR
LISTED
NASDAQ
Arrowhead Pharmaceuticals Reports Fiscal 2024 Third Quarter Results
News Preview
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2024 third quarter ended June 30, 2024. The Company is hosting a conference call today, August 8, 2024, at 4:30 p.m. ET to discuss the results.
“Arrowhead had a very productive quarter with several high-profile presentations at medical and scientific...
Themefolio
Profiler
Peergroup
© BusinessWire
08.08.2024
ARWR
LISTED
NASDAQ
Arrowhead Pharmaceuticals Announces $500 Million Strategic Financing Facility with Sixth Street
News Preview
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has entered into a strategic financing agreement with Sixth Street for significant, long-term, non-dilutive capital to fund innovation and growth opportunities across Arrowhead’s robust and diverse pipeline of RNAi therapeutics. The $500 million senior secured credit facility i...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
